Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04113616
Title An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Kartos Therapeutics, Inc.
Indications

acute myeloid leukemia

Therapies

KRT-232

Decitabine + KRT-232

Cytarabine + KRT-232

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL

Additional content available in CKB BOOST